The effect of Echinacea purpurea on the pharmacokinetics of docetaxel
Article first published online: 20 AUG 2013
© 2013 The British Pharmacological Society
British Journal of Clinical Pharmacology
Special Issue: Cancer Therapeutics Themed Section
Volume 76, Issue 3, pages 467–474, September 2013
How to Cite
Goey, A. K. L., Meijerman, I., Rosing, H., Burgers, J. A., Mergui-Roelvink, M., Keessen, M., Marchetti, S., Beijnen, J. H. and Schellens, J. H. M. (2013), The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. British Journal of Clinical Pharmacology, 76: 467–474. doi: 10.1111/bcp.12159
- Issue published online: 20 AUG 2013
- Article first published online: 20 AUG 2013
- Accepted manuscript online: 23 MAY 2013 06:16AM EST
- Manuscript Accepted: 10 MAY 2013
- Manuscript Received: 12 DEC 2012
- Dutch Cancer Society. Grant Number: UU 2007–3795
- clinical trial;
- Echinacea purpurea;
- herb–drug interactions;
The herbal medicine Echinacea purpurea (E. purpurea) has been shown to induce cytochrome P450 3A4 (CYP3A4) both in vitro and in humans. This study explored whether E. purpurea affects the pharmacokinetics of the CYP3A4 substrate docetaxel in cancer patients.
Ten evaluable cancer patients received docetaxel (135 mg, 60 min IV infusion) before intake of a commercially available E. purpurea extract (20 oral drops three times daily) and 3 weeks later after a 14 day supplementation period with E. purpurea. In both cycles, pharmacokinetic parameters of docetaxel were determined.
Before and after supplementation with E. purpurea, the mean area under the plasma concentration–time curve of docetaxel was 3278 ± 1086 and 3480 ± 1285 ng ml−1 h, respectively. This result was statistically not significant. Nonsignificant alterations were also observed for the elimination half-life (from 30.8 ± 19.7 to 25.6 ± 5.9 h, P = 0.56) and maximum plasma concentration of docetaxel (from 2224 ± 609 to 2097 ± 925 ng ml−1, P = 0.30).
The multiple treatment of E. purpurea did not significantly alter the pharmacokinetics of docetaxel in this study. The applied E. purpurea product at the recommended dose may be combined safely with docetaxel in cancer patients.